The ‘Translator of the Year’ award is presented to a company that has supported an academic lab or therapeutic biotechnology company to successfully translate their science from the laboratory to the manufacturing facility (GMP). To pave the way toward commercialization of the therapy for the benefit of patients.

Criteria:

• Entries must be from an academic lab, therapeutic biotechnology company, consultant, CRO, CMO or CDMO
• Entries must have supported an academic lab or therapeutic biotechnology company to translate their science into GMP successfully

The Phacilitate Young Scientist Award is presented annually for significant research contributions to the field of cell and gene therapy.

Criteria:

• Entries must be for an individual
• Entries must not be dual nominations
• Entries are open to Investigators from academia, research foundations, government, and industry are all eligible to be nominated for the award
• Entries must have between 3-7 years of experience since completion of the university course
• Entries must be under 37 years old on January 1st of the year the award is granted

The ‘Manufacturing Tech Disruptor of the Year’ award is presented to a company or an academic lab who have helped improve and simplify the manufacturing process through innovative new technology. We want to hear from trail blazers who are leading the way for the next generation of therapies.

Criteria:  

• Entries must be from a company or academic lab  

• Entries must have implemented improvements or technology into a real life situation 

The Patient Advocacy Award is awarded to cooperate organisations who foster awareness for cell and gene therapies and support those going through treatment. This award is targeted at corporate companies who place the patient at the heart of their product development.

Criteria:  

• Entries must have a public identity that raises awareness for cell and gene therapies
• Entries must have provided outstanding service to a community of people seeking healthcare
• Entries must have contributed time and service to patient advocacy groups, committees or organisations
• Entries must have company that truly integrates patients, their families, and their caregivers into the planning and development journey

The Patient Advocacy Award is awarded to non profit organizations who foster awareness for cell and gene therapies and support those going through treatment. This award is targeted at non profit companies who place the patient at the heart of their development and patient advocacy organizations who are dedicated to spreading awareness of the potential of CGT.

Criteria: 

• Entries must have a public identity that raises awareness for cell and gene therapies
• Entries must have provided outstanding service to a community of people seeking healthcare
• Entries must have contributed time and service to patient advocacy groups, committees or organizations
• Entries must have company that truly integrates patients, their families, and their caregivers into the planning and development journey

The ‘Women in Advanced Therapies’ award is in recognition of an individual or organization’ that has initiated a call to action to remove barriers and improve and support a diverse working culture across all levels of the Advanced Therapies sector

This award is not limited to women but is inclusive of all people who have made a significant positive impact on the work life of women, examples could include:

• Initiatives to ensure equality of opportunity for all from graduate to board level
• Initiatives aimed at developing women’s leadership potential, including mentor programs, women’s networks and return-to-work programs
• Initiatives showing commitment to inclusion of gender specific considerations (such as paternity, maternity and adoption initiatives, menopause considerations and flexible working)
• Improvement to employee diversity over the past 24 months

This award recognizes sustainable development in the cell and gene therapy industry through innovative and sustainable use of resources and prioritizes the needs of the wider environment and society. This can be a reduced carbon footprint or energy-saving products and methods. This can also include the adoption of a scheme that has made a difference in the attitudes and behavior of staff and resulted in a benefit to the environment or a new partnership that demonstrates tangible evidence of environmental benefit. This can be on a single project, across a series of projects, or through a change process within an organization.

This award recognizes biotech championing therapeutic innovation in cell therapy that is demonstrating a positive potential impact on patients in the future.

Criteria:  

• Entries must have a minimum of phase 1 clinical data 
• Entries Phase 1 data must demonstrate key safety indicators 

This award recognizes biotech championing therapeutic innovation in gene therapy that is demonstrating a positive potential impact on patients in the future.

Criteria:  

• Entries must have a minimum of phase 1 clinical data 
• Entries Phase 1 data must demonstrate key safety indication 

Simon Ellison was a passionate advocate for supply chain innovation and education, and his legacy has inspired this award.

The Simon Ellison Supply Chain Innovation Award recognizes outstanding individuals and organizations that have demonstrated exceptional dedication to the advancement of supply chain innovation and its critical impact on saving patients’ lives.

Criteria:  

• Entries can be a company or individual  
• Entries must have worked directly within the supply chain and logistics roles for at least 4 years  
• Entries must have a passion for supply chain innovation for the benefit of patients 

The Phacilitate Lifetime Achievement Award recognizes a Phacilitate Member who has achieved a lifetime of significant contributions to the field of gene and cell therapy.  

The Awards Judging panel will submit nominations and judge from this selection in tandem with Phacilitate